Form 4: Director David Young Increases Stake in Processa

Processa Pharmaceuticals President of R&D David Young acquired 1,545 shares of common stock at $2.97 per share.

Summary

• David Young, President of Research & Development at Processa Pharmaceuticals, purchased 1,545 shares of common stock on May 15, 2026.
• The transaction was executed at a price of $2.97 per share.
• Following the transaction, David Young directly owns 15,345 shares of common stock.
• The filing includes a correction to a previous Form 4 filed on May 1, 2026, adjusting the purchase price of a prior transaction to $2.71 per share and reducing the previously reported share count by 13 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event; while insider buying is generally bullish, the necessity of correcting a previous filing slightly offsets the sentiment.

Positives

• Insider confidence is demonstrated by the purchase of additional shares by a key executive.
• The reporting person maintains significant indirect holdings through a revocable trust, family entities, and CorLyst, LLC.

Negatives

• The filing required an amendment to correct immaterial errors regarding share counts and pricing from a previous filing.

Risks

• Reliance on internal reporting accuracy for regulatory compliance.

Future Outlook

No specific forward-looking guidance provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that insider buying in small-cap biotechnology firms is often viewed by the market as a signal of management's belief in the company's clinical pipeline progress.

Comparison to Industry Standards

• Insider buying is a standard practice for executives in the pharmaceutical sector to signal alignment with shareholder interests.
• The correction of administrative errors is a common occurrence in SEC reporting and does not typically indicate material financial distress.

Stakeholder Impact

• Shareholders may interpret the purchase as a sign of internal confidence in the company's R&D trajectory.

Next Steps

• Continued monitoring of insider transactions for further accumulation or divestment.

Key Dates

Recommendation

The transaction is a routine insider purchase. While positive, it does not represent a change in the company's fundamental business outlook sufficient to trigger a buy or sell rating.

Keywords

Processa Pharmaceuticals, PCSA, Insider Trading, Form 4, Biotech, Equity Ownership